

## Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Tjalf Ziemssen · Ovidiu A. Bajenaru · Adriana Carrá · Nina de Klippel · João Correia de Sá · Astrid Edland · Jette L. Frederiksen · Olivier Heinzlef · Klimentini E. Karageorgiou · Rafael H. Lander Delgado · Anne-Marie Landtblom · Miguel A. Macías Islas · Niall Tubridy · Yossi Gilgun-Sherki

Published online: 25 November 2014  
© Springer-Verlag Berlin Heidelberg 2014

**Erratum to: J Neurol (2014) 261:2101–2111**  
**DOI 10.1007/s00415-014-7446-0**

The original version of this article unfortunately contained a mistake. The affiliation of the fifth author (João Correia de Sá) is incorrect. The correct affiliation should be:

J. Correia de Sá  
Hospital de Santa Maria, Lisbon, Portugal

---

The online version of the original article can be found under doi:[10.1007/s00415-014-7446-0](https://doi.org/10.1007/s00415-014-7446-0).

---

T. Ziemssen (✉)  
Neurologische Universitätsklinik Klinikum Carl Gustav Carus,  
Fetscherstraße 74, 01307 Dresden, Germany  
e-mail: Tjalf.Ziemssen@uniklinikum-dresden.de

O. A. Bajenaru  
Carol Davila University of Medicine and Pharmacy, Bucharest,  
Romania

A. Carrá  
Hospital Británico de Buenos Aires, Buenos Aires, Argentina

N. de Klippel  
Virga Jessaziekenhuis, Hasselt, Belgium

J. Correia de Sá  
Hospital de Santa Maria, Lisbon, Portugal

A. Edland  
Central Hospital of Buskerud, Drammen, Norway

J. L. Frederiksen  
Glostrup Hospital, University of Copenhagen, Glostrup,  
Denmark

O. Heinzlef  
Tenon Hospital, Paris, France

K. E. Karageorgiou  
General Hospital of Athens, Athens, Greece

A.-M. Landtblom  
Department of Neurology and Department of Clinical and  
Experimental Medicine, University of Linköping, Linköping,  
Sweden

A.-M. Landtblom  
Department of Medical Specialists and Department of Medicine  
and Health Sciences, Linköping University, Motala, Sweden

M. A. Macías Islas  
Central University of Guadalajara, Guadalajara, Jalisco, Mexico

N. Tubridy  
School of Medicine and Medical Science, Dublin University,  
Dublin, Ireland

Y. Gilgun-Sherki  
Teva Pharmaceuticals Industries Ltd, Petach Tikva, Israel